Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes

Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes


Sunday, June 4, 2017
7:00 PM - 9:00PM

Hilton Chicago
720 S. Michigan Avenue
International Ballroom North (Lobby Level)

Chicago, IL 60605
Phone: (312) 922-4400

Overview

Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes is a live symposium to be held adjunct to the annual meeting in Chicago. The management of advanced forms of lung cancer has been transformed in recent years because of remarkable developments in molecular diagnostics and new therapies. The targeting of known oncogenic drivers has allowed for the development of strategies that aim to improve efficacy and minimize toxicity compared with previous standards of care. Indeed, personalized care is now the standard of care in non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have brought hope to patients with several types of cancer in multiple lines of therapy, including epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-translocated NSCLC. In patient populations that have received targeted treatments, impressive clinical benefit has been achieved with TKIs that target mutated EGFR or ALK. These changes are welcome, and the field continues to move forward, with new diagnostic techniques and an ever-expanding array of therapeutic options in the different lines of therapy. The continual advances in the treatment of patients with oncogenic driver–mutated NSCLC create practice and educational gaps for clinical oncologists who strive to maintain state-of-the-art care for their patients. To meet this educational need, this interactive live symposium has assembled internationally recognized experts in lung cancer research and care to provide cutting-edge approaches that can be applied immediately to clinical practice.

Key topics to be addressed include:

  • The landscape of actionable oncogenic drivers in lung cancer in 2017
  • Choosing therapy for patients with EGFR-mutated NSCLC
  • Assessing and responding to acquired resistance
  • Therapeutic options for patients with ALK- and ROS1-rearranged lung cancer

The symposium will be held at the Hilton Chicago, on June 4, 2017, from 7:00 PM-9:00 PM. Please join us in Chicago for expert advice on oncogene-targeted therapy in lung cancer. This is a program you won’t want to miss!

Target Audience

This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives

  • Apply clinical trial evidence for decision making to personalize care in the frontline setting of NSCLC with actionable mutations
  • Outline multidisciplinary methods to facilitate tumor tissue characterization, rebiopsy, or liquid biopsies to identify actionable mutations in multiple lines of care for patients with lung cancer
  • Assess current and emerging strategies to address the problem of acquired resistance and relapse in patients with NSCLC
  • Personalize care via the use of tumor- and patient-specific characteristics for patients with advanced forms of NSCLC beyond disease progression


Chair

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By